Victor Meza Kyaruzi*, Emmanuel Mduma, Berjo Takoutsing, Ahmed Abdelhammed, Franck Sikakulya, Emmanuel Wekesa, Ramadhani Ngamba, Deodatus Sabas, Happines Rabiel, Zarina Shabhay, Laurent Mchome, Ignatius Esene and Amos Mwakigonja
Volume4-Issue1
Dates: Received: 2023-01-10 | Accepted: 2023-01-28 | Published: 2023-01-31
Pages: 126-133
Abstract
Background: Gliomas are the most common solid malignant tumors of the brain; diffuse gliomas pose a remarkable conundrum on treatment strategy. WHO Grade IV (Glioblastomas) delineate a refractory resistance to treatment even with standard combination regimen therapy of surgery, chemotherapy and radiation therapy causing increased recurrence rate with a median survival of less than one year. Management of gliomas is precluded by several factors including intra and inter tumoral heterogeneity, genomic landscape and microenvironment immunosuppression ability, which spell the inflicted pathways that counteract the therapeutic interventions. This is systematic review aiming to evaluate the effect of Tumor Mutation Burden (TMB) and Tumor Microenvironment (TME) as biomarkers of treatment outcome and prognosis of gliomas.
Methods and Analysis: This systematic Review and Meta-analysis will consider the PRISMA 2020 guideline correspondence. For source of literature evidence several electronic databases including EMBASE, PubMed, Cochrane Library, SCOPUS, Web of Science, Semantic Scholar and Google scholar will be searched. All non-RCTs peer reviewed original research articles addressing the prognostic role of tumor mutation burden, tumor mutation pathways, microenvironment will be included, and data will be extracted using the Ms Excel Sheets. Studies with homogeneity and low risk of bias according to NOS 4-9 will constitute a Meta-analysis for evaluating the effect of TMB, Mutation pathways and Microenvironment for treatment outcome and prognosis of glioma.
Ethical Consideration and Dissemination: Ethical approval does not apply for there is no human participant involvement in this review study .The findings of this study will be disseminated at scientific conferences and the manuscript for publication will be submitted for publication to a reputable peer reviewed journal of Neurosurgery. This review was registered at PROSPERO CRD42022377829.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1656
Certificate of Publication
Copyright
© 2023 Kyaruzi VM, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Kyaruzi VM, Mduma E, Takoutsing B, Abdelhammed A, Sikakulya F, Wekesa E, Ngamba R, Sabas D, Rabiel H, Shabhay Z, Mchome L, Esene I, Mwakigonja A. Tumor Mutation Burden and Tumor Microenvironment as Biomarkers of Glioma Treatment Outcome and Prognosis: A Systematic Review and Meta-Analysis Protocol. 2023 Jan 31; 4(1): 126-133. doi: 10.37871/ jbres1656, Article ID: JBRES1656, Available at: https://www.jelsciences.com/articles/jbres1656.pdf
Subject area(s)
References
- Ahmad H, Fadul CE, Schiff D, Purow B. Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas. Neurooncol Pract. 2019 Dec;6(6):424-427. doi: 10.1093/nop/npz016. Epub 2019 Apr 7. PMID: 31832212; PMCID: PMC6899050.
- Yu G, Pang Y, Merchant M, Kesserwan C, Gangalapudi V, Abdelmaksoud A, Ranjan A, Kim O, Wei JS, Chou HC, Wen X, Sindiri S, Song YK, Xi L, Kaplan RN, Armstrong TS, Gilbert MR, Aldape K, Khan J, Wu J. Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers (Basel). 2021 Dec 3;13(23):6092. doi: 10.3390/cancers13236092. PMID: 34885201; PMCID: PMC8657099.
- Kang K, Xie F, Wu Y, Wang Z, Wang L, Long J, Lian X, Zhang F. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Int Immunopharmacol. 2021;96:107610. doi: 10.1016/j.intimp.2021.107610.
- Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccines Immunother. 2020;16(1):112-115. doi: 10.1080/21645515.2019.1631136.
- Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021 Mar 1;27(5):1236-1241. doi: 10.1158/1078-0432.CCR-20-3054. Epub 2020 Nov 16. PMID: 33199494.
- Alghamri MS, Thalla R, Avvari RP, Dabaja A, Taher A, Zhao L, Ulintz PJ, Castro MG, Lowenstein PR. Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. doi: 10.1093/noajnl/vdaa042. PMID: 32642696; PMCID: PMC7212865.
- Su J, Long W, Ma Q, Xiao K, Li Y, Xiao Q, Peng G, Yuan J, Liu Q. Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. Front Genet. 2019 Nov 15;10:1143. doi: 10.3389/fgene.2019.01143. PMID: 31803233; PMCID: PMC6872675.
- Cooper LAD, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, Kurc T, Van Meir EG, Saltz JH, Moreno CS, Brat DJ. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012;180(5):2108-2119. doi: 10.1016/j.ajpath.2012.01.040.
- Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med. 2018 Aug;12(4):426-439. doi: 10.1007/s11684-018-0663-7. Epub 2018 Aug 10. PMID: 30097962.
- Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, Liang M, Deng S, Zhang X, Wang W, Tan Y, Xu Y, Luo T. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer. 2020 Mar 12;20(1):213. doi: 10.1186/s12885-020-6658-1. PMID: 32164609; PMCID: PMC7069200.
